- Chemotherapy
- Alkylating Agents
- Nucleoside Analogues
- Anthracycline Derivatives
- Others
- Radiotherapy
- Monoclonal Antibodies
- Stem Cell Transplantation
The global Follicular Lymphoma Treatment Market size valued at USD 3.2 billion in 2021 and expected to reach USD 5.24 billion by 2028, at a CAGR of 7.3% during the forecast period 2022 to 2028. Follicular lymphoma treatment market is poised to grow at significant rate owing to increase in the R&D activities for the innovation newer therapies and drugs. Most of the international players are actively involved in the development of newer products. For instance, in December 2015, Novartis announced phase IIa study results of CTL019 used in the treatment of certain types of lymphoma including follicular lymphoma. Moreover, rising adoption of monoclonal antibodies for targeted therapies propels the follicular lymphoma treatment market. Furthermore, acquisitions and mergers, collaborations, product approvals, and product launchings are the strategies followed by the market players for gaining larger revenue share in follicular lymphoma treatment market. For instance, in February 2017, Health Canada approved Roche’s Gazyva (Obinutuzumab) for patients with previously treated follicular lymphoma. In addition, in August 2017, Epizyme, Inc. and US Oncology Research are collaborated to identify the non-Hodgkin lymphoma patients with EZH2 mutations and eligible patients are directed to ongoing phase 2 clinical trial of Tazemetostast in diffuse large B-cell lymphoma and follicular lymphoma. Follicular lymphoma is the second most common indolent non-Hodgkin’s lymphoma and it develops when the body makes abnormal B-lymphocytes in lymph nodes. The symptoms associated with follicular lymphoma include enlargement of lymph nodes in neck, abdomen, and groin, weight loss, difficulties in breathing, fatigue, and night sweats. Follicular lymphoma is diagnosed by biopsy, blood tests, and X-rays among others. Follicular lymphoma can be treated with chemotherapy, radiation therapy, targeted therapy, and stem cell transplant.
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
Rise in prevalence of follicular lymphoma, family history of blood disorders, increase in R&D activities for the innovation of newer drugs, and technological advancements in disease diagnosis are anticipated to fuel the follicular lymphoma treatment market. Moreover, promising pipeline products, innovation of newer therapies such as monoclonal antibodies, and government initiations for the cancer management are expected to boost the market over the forecast period. However, stringent regulatory policies for drug approval, the high cost of treatment, and adverse effects associated with the treatment are expected to hamper the growth of follicular lymphoma treatment market over the forecast years.
2021 is the base year and 2028 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
[urltag url='request-table-of-content']